Hers vs Spry
Hers and Spry both sell semaglutide and tirzepatide; this is how their prices, coverage and records differ.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Hers
Best for: coverage in all 50 states, which most sellers will not confirm
Visit Hers →
If you are choosing between Hers and Spry, price alone will not settle it. Both prescribe semaglutide and tirzepatide, so moving from one to the other would not change your drug. Hers leads our six-part score, 6.6 to 6.0. One of the two has an FDA warning letter on record, covered below.
Hers vs Spry price
Hers and Spry start at the same figure, $199 a month, so the entry price does not separate them. Look at what each price covers and at the per-drug prices below.
Drug by drug: Semaglutide costs the same at both, $199 a month; tirzepatide costs the same at both, $299 a month.
Medications and formats
Both sell semaglutide and tirzepatide.
On format, Hers prices compounded injections and brand-name pens, while Spry prices compounded injections.
If you want the FDA-approved brand rather than a compounded version, Hers is the only one of the two with a brand-name price.
Where each one treats patients
Hers lists 50 states, and Spry does not publish where it ships.
Pricing
Hers
Brand Zepbound from $299/mo medication-only; requires Hers Weight Loss Membership ($149/mo)
Spry
What each price covers
Hers' price also covers the medication itself, which Spry does not claim.
Hers is silent on shipping and lab work.
Spry does not say what its price includes.
That matters most for the drug: unless Spry confirms otherwise, budget for medication on top of its listed price.
Hers
Covered by the monthly price
Medication
In the price
Clinician visits
Charged on top
Shipping
Not stated
Lab work
Not stated
Coaching
Charged on top
Spry
Inclusions not disclosed.
Where each one scores higher
Overall, Hers scores 6.6 and Spry 6.0 out of 10.
Hers is stronger on trust & safety (5.5 vs 3.5) and accessibility (10.0 vs 5.0).
Spry is stronger on support (5.0 vs 3.0).
Value, effectiveness and user experience are within half a point.
Hers
6.6/10
Spry
6.0/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
FDA warning letters
The FDA sent Hers a warning letter dated September 9, 2025 (letter 716825), and it is still open.
Spry has no FDA warning letter on record with us.
Features & Coverage
| Feature | Hers | Spry |
|---|---|---|
| Starting Price | $199/mo | $199/mo |
| Features | 2 features | ✓5 features |
| States Available | 50 | Not disclosed |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warning Letters | 1 letter | ✓None |
About Hers
Hers is the women-focused telehealth brand from Hims and Hers. It sells compounded semaglutide on a 6-month plan.
Read our full Hers review →About Spry
Semaglutide compounded is $199/mo here and tirzepatide $299/mo. Three longevity peptides sit alongside, BPC-157, NAD+ and sermorelin, at $249-$299/mo. Spry names three co-founders, holds LegitScript certification, ties nobody to a contract, and has a nurse practitioner look at intake inside 24 hours. One caution: an 'FDA Approved' badge appears on the site, and compounded GLP-1s are not finished products carrying FDA approval.
Read our full Spry review →Pros & Cons
Hers
What we like
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication
- Serves all 50 states
Watch-outs
- Not included in the monthly price: clinician visits, coaching
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- The FDA has issued Hers a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
Spry
What we like
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- We found no FDA warning letters issued to Spry
Watch-outs
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
Hers wins this one, 6.6 to 6.0, above all for coverage in all 50 states, which most sellers will not confirm. Spry fits better if seeing what it charges before you answer any medical questions is your priority.
Choose Hers if…
You want coverage in all 50 states, which most sellers will not confirm and an opening price near $199 a month.
Choose Spry if…
You want seeing what it charges before you answer any medical questions and an opening price near $199 a month.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
DudeMeds
Compounded semaglutide at $175/month
From $175/mo
Get started →Oak
Semaglutide at $119/month, 37% below the typical price
From $119/mo
Get started →Bodybuilding Health+
Seeing what it charges before you answer any medical questions
From $179/mo
Get started →Hers vs Spry: FAQ
Close alternatives to Hers and Spry
- Hers vs Hims
- Hers vs Care Bare Rx
- Hers vs Concierge MD LA
- Hers vs Corsica Health
- Spry vs Hims
- Spry vs Curex
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.